![]() |
Name |
Chermesinone B
|
Molecular Formula | C18H20O5 | |
IUPAC Name* |
(6aR,9S,9aS)-3,6a-dimethyl-9-[(2S)-2-methylbutanoyl]-9,9a-dihydrofuro[2,3-h]isochromene-6,8-dione
|
|
SMILES |
CC[C@H](C)C(=O)[C@@H]1[C@H]2C3=COC(=CC3=CC(=O)[C@@]2(OC1=O)C)C
|
|
InChI |
InChI=1S/C18H20O5/c1-5-9(2)16(20)14-15-12-8-22-10(3)6-11(12)7-13(19)18(15,4)23-17(14)21/h6-9,14-15H,5H2,1-4H3/t9-,14-,15+,18-/m0/s1
|
|
InChIKey |
MZMGICPQNSXAGE-SRSSHDMCSA-N
|
|
Synonyms |
Chermesinone B; CHEMBL1801780; CHEBI:67397; BDBM50347537; Q27135857; rel-(6aR,9S,9aS)-3,6a-Dimethyl-9-[(2S)-2-methylbutanoyl]-9,9a-dihydro-6H-furo[2,3-h]isochromene-6,8(6aH)-dione
|
|
CAS | NA | |
PubChem CID | 53355010 | |
ChEMBL ID | CHEMBL1801780 |
Chemical Classification: |
|
|
---|
Molecular Weight: | 316.3 | ALogp: | 1.7 |
HBD: | 0 | HBA: | 5 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 69.7 | Aromatic Rings: | 3 |
Heavy Atoms: | 23 | QED Weighted: | 0.59 |
Caco-2 Permeability: | -4.697 | MDCK Permeability: | 0.00001920 |
Pgp-inhibitor: | 0.943 | Pgp-substrate: | 0.004 |
Human Intestinal Absorption (HIA): | 0.032 | 20% Bioavailability (F20%): | 0.421 |
30% Bioavailability (F30%): | 0.009 |
Blood-Brain-Barrier Penetration (BBB): | 0.914 | Plasma Protein Binding (PPB): | 64.95% |
Volume Distribution (VD): | 1.975 | Fu: | 43.49% |
CYP1A2-inhibitor: | 0.322 | CYP1A2-substrate: | 0.329 |
CYP2C19-inhibitor: | 0.212 | CYP2C19-substrate: | 0.755 |
CYP2C9-inhibitor: | 0.076 | CYP2C9-substrate: | 0.042 |
CYP2D6-inhibitor: | 0.012 | CYP2D6-substrate: | 0.084 |
CYP3A4-inhibitor: | 0.477 | CYP3A4-substrate: | 0.483 |
Clearance (CL): | 6.028 | Half-life (T1/2): | 0.577 |
hERG Blockers: | 0.086 | Human Hepatotoxicity (H-HT): | 0.704 |
Drug-inuced Liver Injury (DILI): | 0.694 | AMES Toxicity: | 0.356 |
Rat Oral Acute Toxicity: | 0.61 | Maximum Recommended Daily Dose: | 0.879 |
Skin Sensitization: | 0.868 | Carcinogencity: | 0.873 |
Eye Corrosion: | 0.031 | Eye Irritation: | 0.037 |
Respiratory Toxicity: | 0.956 |